Suppr超能文献

奥比他韦/帕利瑞韦/利托那韦、达沙布韦和利巴韦林成功治疗丙型肝炎病毒相关冷球蛋白血症:一例报告

Successful treatment of HCV-associated cryoglobulinemia with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin: A case report.

作者信息

Makara Mihály, Sulyok Mihály, Csacsovszki Ottó, Sulyok Zita, Vályi-Nagy István

机构信息

St István and St László Hospital, Hepatology Center, 1097, Nagyvárad sqr. 1, Budapest, Hungary.

Semmelweis University, Doctoral School for Clinical Medicine, 1085, Üllői str. 26, Budapest, Hungary; Eberhard Karl University, Institute for Tropical Medicine, 72074, Wilhelmstr. 27, Tuebingen, Germany.

出版信息

J Clin Virol. 2015 Nov;72:66-8. doi: 10.1016/j.jcv.2015.09.003. Epub 2015 Sep 16.

Abstract

Cryoglobulinemia is an important extrahepatic manifestation of chronic hepatitis C virus infection. Current treatments are suboptimal, resulting in relapse or refractoriness in 30-40% of patients. Hereby, we describe the case of a 40-year old man with severe hepatitis C virus-associated cryoglobulinemia, effectively treated with an interferon-free combination regimen. The patient was treated for 12 weeks with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin. Rapid clinical and immunological response, i.e., the resolution of symptoms and disappearance of serum cryoglobulins, ensued as early as 4 weeks after initiating direct acting antiviral therapy. Our reported case directs the attention to the possible consequences and importance of new, effective, interferon-free antiviral treatments in devastating lymphoproliferative and immunological manifestations of chronic hepatitis C virus infection.

摘要

冷球蛋白血症是慢性丙型肝炎病毒感染的一种重要肝外表现。目前的治疗效果欠佳,导致30%-40%的患者复发或难治。在此,我们描述了一名40岁患有严重丙型肝炎病毒相关冷球蛋白血症的男性患者,其通过无干扰素联合方案得到有效治疗。该患者接受了12周的ombitasvir/paritaprevir/ritonavir、达沙布韦和利巴韦林治疗。早在开始直接抗病毒治疗4周后,就出现了快速的临床和免疫学反应,即症状消退和血清冷球蛋白消失。我们报告的病例提醒人们关注新型、有效、无干扰素抗病毒治疗在慢性丙型肝炎病毒感染所致严重淋巴增殖性和免疫表现中的可能后果及重要性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验